Treatment of patients with lamivudine (3TC) results in loss of detectable levels of hepatitis B virus (HBV) DNA from serum; however, the relapse rate, with regard to both reappearance of virus in the bloodstream and hepatic inflammation, is high when therapy is terminated. Although the rebound observed in patients has also been seen in animal hepadnavirus models, rebound has not been analyzed i...

To investigate the infectivity of hepatitis B virus (HBV) from mothers to their newborn offspring, HBV-DNA in plasma and peripheral mononuclear cells from 28 antihepatitis Be positive, hepatitis B surface antigen positive carrier mothers was examined by a highly sensitive polymerase chain reaction/Southern hybridisation technique. HBV specific DNA was detected in three maternal mononuclear cell...

The aim of this study was to investigate the diagnostic value of the serum markers HBsAg and HBeAg and PreS1 protein (PreS1-Ag) in quantifying the levels of hepatitis B virus (HBV) DNA in patients with chronic hepatitis B (CHB). One thousand CHB patients were recruited from Beijing You'an Hospital between June and December 2012. Serum HBsAg and HBeAg levels were detected by electrochemiluminesc...

Hepatitis B virus (HBV) infection is the major cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) worldwide, especially in the Asia-Pacific region. Several hepatitis B viral factors predictive of clinical outcomes in HBV carriers have been identified. The Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-HBV (REVEAL-HBV) study from Taiwan illustr...

AIM To evaluate the efficacy of interruption of intrauterine infection of HBV with HBIG in pregnant women with positive HBeAg and HBsAg. METHODS A prospective randomized controlled trial was adopted. Sixty cases with positive HBeAg and HBsAg were coincident with the criteria of inclusion, and 8 cases were excluded. Fifty-two cases were analyzed (28 cases in trial group and 24 in control group...

conclusions it is concluded that most hbeag negative hepatitis b patients with serum hbv dna level of 2000-20000 iu/ml, persistent normal alt concentration, and no or mild liver damage on biopsy can be clinically managed as hbv inactive carriers. results two hundred forty-three hbeag negative hepatitis b patients were stratified into three groups based on to their hbv dna level including group ...

Background and Aims: chronic HBV infection is one of the most common viral infections in worldwide which many factors such as genetic factors are involved in pathogenesis of disease. Gamma interferon (IFN-γ) and its receptor (INFGR) play a critical role in the immune response to HBV infection. Single nucleotide polymorphisms (SNPs) are effective on level of gene expression, The aim of thi...

BACKGROUND Body fluids such as saliva, urine, sweat, and tears from hepatitis B virus (HBV) carriers are potential sources of HBV transmission. METHODS Thirty-nine children and 8 adults who were chronically infected with HBV were enrolled. Real-time polymerase chain reaction was used for the quantification of HBV DNA. RESULTS HBV DNA was detected in 73.7% of urine samples (14 of 19), 86.8% ...

PURPOSE: To determine prevalence of positive HBV DNA in liver tissue samples in patients with chronic HCV infection (CHCV) and to investigate whether there is an association between it and underlying clinical condition. METHODE: For the period 2004 – 2010 in the Gastroenterology Clinic at the Military Medical Academy – Sofia, 96 patients CHCV (77% males, 23% females, mean age 50, 5 ± 10, 02 yea...

Hepatitis B virus (HBV) remains a global health threat as chronic HBV infection may lead to liver cirrhosis or cancer. Current antiviral therapies with nucleoside analogues can inhibit the replication of HBV, but do not disrupt the already existing HBV covalently closed circular DNA. The newly developed CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated 9...